Imagine a world where we could prevent one of the most devastating complications in premature infants—bronchopulmonary dysplasia (BPD). This is the promise of zelpultide alfa, a groundbreaking therapy that’s turning heads in the neonatal intensive care world. But here’s where it gets controversial: could this be the first truly physiological drug to prevent BPD, or are we getting ahead of ourselves? Let’s dive into the details and explore why this could be a game-changer—or a topic of heated debate.
In a recent phase 1b study published in Frontiers in Pediatrics, researchers evaluated zelpultide alfa, an investigational recombinant human surfactant protein D, in preterm neonates at high risk of developing BPD. Led by Dr. Daniele De Luca, a professor of Neonatology at Paris Saclay University and Division Chief of the NICU at Béclère Hospital, the study aimed to address a critical gap in neonatal care. BPD remains one of the most severe long-term complications of prematurity, and current treatments often fall short. Unlike traditional surfactants, zelpultide alfa doesn’t just support lung function—it actively regulates innate immunity by clearing pathogens and reducing pulmonary inflammation, a dual action that’s sparking excitement and debate in the medical community.
The phase 1b trial enrolled 37 intubated, mechanically ventilated preterm infants who received at least one surfactant treatment within 96 hours of birth. The primary focus was safety and tolerability, and the results were encouraging. Zelpultide alfa demonstrated a favorable safety profile at its highest dose of 6 mg/kg. While 92.9% of infants receiving zelpultide alfa experienced at least one adverse event, compared to 100% in the air-sham group, mortality was 21% in the treatment group versus 0% in the control group. Importantly, none of the deaths were attributed to the study drug. And this is the part most people miss: despite the mortality rate, the drug showed promising early efficacy signals, with a BPD incidence of 32.1% in the treatment group compared to 66.7% in the control group. Infants receiving zelpultide alfa also spent significantly fewer days on mechanical ventilation—17.7 days versus 25.8 days.
These findings have paved the way for a pivotal international Phase 2b/3 program, with the European Medicines Agency Pediatric Committee (PDCO) approving the Pediatric Investigation Plan (PIP) in August 2025. The Phase 2b portion will assess two dose levels in 150 patients, followed by a Phase 3 expansion enrolling approximately 216 additional infants. But here’s the bold question: is zelpultide alfa the future of BPD prevention, or are we overlooking potential long-term risks?
In a Q&A with Contemporary Pediatrics, Dr. De Luca highlighted the drug’s unique mechanism of action. Unlike steroids, which are often used to combat inflammation but come with significant side effects, zelpultide alfa is a replacement therapy that mimics a naturally occurring protein. This physiological approach is not only innovative but also aligns with the body’s own processes, a point that’s both exciting and contentious. Critics argue that while the early data is promising, larger trials are needed to fully understand the drug’s safety and efficacy.
Dr. De Luca is optimistic, stating, ‘If these data are confirmed, zelpultide alfa could be a game changer.’ But he also acknowledges the challenges ahead, particularly in optimizing dosing and ensuring long-term safety. As the trial moves forward in countries like Italy, Spain, Israel, France, Germany, Belgium, Poland, Argentina, Australia, and the United States, the medical community is watching closely. Will zelpultide alfa revolutionize BPD prevention, or will it face unexpected hurdles? Only time will tell.
What do you think? Is zelpultide alfa the breakthrough we’ve been waiting for, or are there still too many unknowns? Share your thoughts in the comments below!
